Leveragen, a pioneering biotechnology company based in Woburn, Massachusetts, specializing in next-generation in vivo antibody discovery platforms, has announced a strategic partnership with Propeller Bio, a newly established biotechnology company focused on antibody and protein-based therapeutics. This collaboration involves Propeller Bio providing support for the ongoing development of Leveragen’s innovative antibody discovery platforms through a strategic investment. In return, Leveragen will grant Propeller Bio access to its exclusive suite of proprietary antibody mouse models, including the cutting-edge Singularity Sapiens Mouse known for its fully human single-domain antibody discovery platform. The Singularity Sapiens Mouse is engineered to elicit robust immune responses across a wide range of antigens, facilitating the efficient discovery of fully human VH-only antibodies with exceptional developability and diverse epitope coverage.
This platform accommodates various therapeutic formats such as bispecifics, antibody-drug conjugates, CAR-T therapies, and mRNA-encoded antibodies, positioning it as a versatile tool for biologics development. Dr. Weisheng Chen, Founder and CEO of Leveragen, expressed enthusiasm about the collaboration with Dr. David Shen and the team at Propeller Bio, highlighting Dr. Shen’s impressive track record in delivering innovative biomedicines to patients in need. Dr. Shen, Founder and CEO of Propeller Bio, lauded Leveragen’s Singularity Sapiens Mouse as a distinctive platform for antibody discovery, providing high-quality, in vivo matured human VH domains with remarkable diversity and developability. This partnership underscores Leveragen’s expanding role as a trusted discovery partner for biotech companies driving advancements in biologics innovation. Leveragen and Propeller Bio’s joint efforts exemplify a commitment to pushing the boundaries of biotechnology for the betterment of healthcare and patients worldwide.
Tags: biotechnology
Read more from finance.yahoo.com